Research and Markets (http://www.researchandmarkets.com/research/6p737b/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- List of Tables
- List of Figures
- Introduction
- Idiopathic Pulmonary Fibrosis Overview
- Therapeutics Development
- Pipeline Products for Idiopathic Pulmonary Fibrosis - Overview
- Pipeline Products for Idiopathic Pulmonary Fibrosis - Comparative Analysis
- Idiopathic Pulmonary Fibrosis - Therapeutics under Development by Companies
- Idiopathic Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes
- Idiopathic Pulmonary Fibrosis - Pipeline Products Glance
- Clinical Stage Products
- Early Stage Products
- Unknown Stage Products
- Idiopathic Pulmonary Fibrosis - Products under Development by Companies
- Idiopathic Pulmonary Fibrosis - Products under Investigation by Universities/Institutes
- Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development
- AdAlta Pty Ltd.
- Aeolus Pharmaceuticals, Inc.
- Afferent Pharmaceuticals, Inc.
- AnaMar AB
- Biogen, Inc.
- Bioneer Corporation
- BiOrion Technologies B.V.
- Bristol-Myers Squibb Company
- Carolus Therapeutics, Inc.
- Celgene Corporation
- Chong Kun Dang Pharmaceutical Corp.
- Compugen Ltd.
- F. Hoffmann-La Roche Ltd.
- FibroGen, Inc.
- Galapagos NV
- GenKyoTex S.A.
- Gilead Sciences, Inc.
- Histocell S.L.
- iBio, Inc.
- ImmuneWorks, LLC
- Inventiva SAS
- Isarna Therapeutics GmbH
- MedImmune, LLC
- Moerae Matrix, Inc.
- MorphoSys AG
- MSM Protein Technologies, Inc.
- Pacific Therapeutics Ltd.
- Pharmaxis Limited
- Progenra, Inc.
- Respira Therapeutics, Inc.
- Rhizen Pharmaceuticals SA
- Ribomic Inc.
- Sanofi
- Teva Pharmaceutical Industries Limited
- Yuhan Corporation
For more information visit http://www.researchandmarkets.com/research/6p737b/idiopathic
View source version on businesswire.com: http://www.businesswire.com/news/home/20160106006153/en/
